Skip to main content
Premium Trial:

Request an Annual Quote

Population Genetics Technologies Receives $3.2M in Series A Funding

NEW YORK (GenomeWeb News) – Population Genetics Technologies said today that it has secured a £2,000,000 ($3.2 million) investment from previous investors in the privately held genomics analysis technologies firm.

The company said it earned this second tranche of the Series A funding by meeting certain commercial and developmental milestones set by its principal investors.

The Cambridge, UK-based firm's initial seed funding came from the Wellcome Trust, and its Series A investors include Auriga Partners, Beringea, and Compass Genetics Investors.

PGT said it has developed technologies that will "dramatically reduce the costs of performing large-scale population studies" and will "allow the detection and characterization of rare allelic variations in disease phenotypes."

"This latest round of investment will allow us to not only progress our development activities but also to begin pre-commercial investigations of the various markets, business models and partners where our technologies can add value," PGT CEO Mel Kronick said in a statement.

Among PGT's founders are Nobel Laureate Sydney Brenner, Applied Biosystems and Lynx Therapeutics Co-founder Sam Eletr, and Molecular Tool and Red Abbey Ventures Founder Philip Goelet.

The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.